Automated planar electrode electrophysiology in drug discovery: examples of the use of QPatch in basic characterization and high content screening on Na(v), K(Ca)2.3, and K(v)11.1 channels.
Planar chip technology has strongly facilitated the progress towards fully automated electrophysiological systems that, in contrast to the traditional patch clamp technology, have the capability of parallel compound testing. The throughput has been increased from testing below 10 compounds per day to a realized capacity approaching high throughput levels. Many pharmaceutical companies have implemented automated planar chip electrophysiology in their drug discovery process, particularly at the levels of lead optimization, secondary screening and safety testing, whereas primary screening is generally not performed. In this review, we briefly discuss the technology and give examples from selected NeuroSearch ion channel programs, where one of the systems, the QPatch, has been evaluated for use in lead optimization and primary screening campaigns, where high information content was a requirement.
Korsgaard
Mads P G
MP
NeuroSearch A/S, Pederstrupvej 93, DK 2750 Ballerup, Denmark.
Strøbaek
Dorte
D
Christophersen
Palle
P
D000818:Animals; D055808:Drug Discovery / Q000295:instrumentation / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004594:Electrophysiology / Q000295:instrumentation* / Q000379:methods; D006801:Humans; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; D007473:Ion Channels / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D015221:Potassium Channels; D015222:Sodium Channels
D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; D007473:Ion Channels; D015221:Potassium Channels; D015222:Sodium Channels